相关实验视频

Updated: Jun 25, 2025

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

什么比例的BRCA相关的乳腺癌是人类表皮生长因子2-低,并有资格额外的向治疗?

Emily Forester¹, Aakash Belsare², Dong Won Kim³

¹Division of Breast Surgical Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Rowan-Virtua School of Osteopathic Medicine, Stratford, New Jersey.

The Journal of surgical research

|May 22, 2024

概括

许多患有生殖系BRCA1/2 (gBRCA1/2) 变异的患者,以前被诊断为三阴性乳腺癌 (TNBC) 或激素受体阳性/HER2-阴性 (HR+/HER2-) 乳腺癌,现在被归类为HER2-低. 这种重新分类可能为这些患者提供新的向治疗选择.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
乳腺癌研究研究乳腺癌研究

背景情况:

DESTINY-B04试验确定了HER2低表达在乳腺癌中的临床意义.
生殖系BRCA1 (gBRCA1) 致病变体经常与三阴性乳腺癌 (TNBC) 相关.
对于gBRCA1/2患者从HER2-低向治疗中获益的潜力仍然在很大程度上未被描述.

研究的目的:

确定患有生殖系BRCA1或BRCA2 (gBRCA1/2) 致病变体的患者的比例,这些患者可以被归类为HER2-low.
评估gBRCA1/2患者在基于HER2-低状态的基础上获得新型向治疗的资格.

主要方法:

从2000年到2021年,对具有gBRCA1/2的侵袭性乳腺癌患者进行了回顾性图表审查.
单独记录同步或超时的逆侧乳腺癌.
使用免疫组织化学和光 in situ 杂交来确定 HER2 状态;不包括不完整 HER2 数据的病例.

主要成果:

在85名gBRCA1/2患者的95种乳腺癌中,43%是TNBC,40%是HR+/HER2-和17%是HER2-阳性.
82%的HR+/HER2-和66%的TNBC病例被重新分类为HER2-低.
在64%的gBRCA1癌症和58%的gBRCA2癌症中观察到HER2低分类.

结论:

相当数量的gBRCA1/2患者先前有TNBC或HR+/HER2-诊断,现在符合HER2-低标准.
这些患者在转移性环境中可能是trastuzumab deruxtecan的候选人.
在此疗法转换后,需要进一步评估治疗结果.

关键词:

乳腺癌乳腺癌乳腺癌乳腺癌1型基因致病变体基因致病变体在HER2-低的水平下.人类表皮生长因子2 2

更多相关视频

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...